Moderna Inc.’s Covid-19 vaccine generated a robust neutralizing antibody response after two doses in children aged 6 to under 12 years, said the company in a statement on Monday.
It said the data showed two 50 microgram doses of the vaccine, half the strength of the doses used in the vaccine given to adults, given 28 days apart was generally well-tolerated.
The majority of side effects were mild or moderate in severity, the company said. The most common solicited adverse events were fatigue, headache, fever and injection site pain. “We are encouraged by the immunogenicity and safety profile of mRNA-1273 in children aged 6 to under 12 years and are pleased that the study met its primary immunogenicity endpoints," said Stéphane Bancel,